A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.
Scott Olson | Getty Images
The Food and Drug Administration on Tuesday approved Eli Lilly‘s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S.
The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early symptomatic Alzheimer’s disease, according to the company.
Nearly 7 million Americans have the condition, the fifth-leading cause of death for adults over 65, according to the Alzheimer’s Association. By 2050, that group is projected to rise to almost 13 million in the U.S.
It’s a long-awaited win for Eli Lilly after donanemab faced obstacles in its path to market. The FDA rejected the drug’s approval last year due to insufficient data, then…
